BELMONT, Calif., May 8, 2026 /PRNewswire/ -- Duno Health, Inc., a leading consumer health sciences company, announced the launch of Youth & Vitality, a new daily supplement formulated with NAD+ precursor and essential vitamins to support cellular renewal and whole body health. Continue Reading Product description Differences between discrete categorised variable of the entire sample population Modern Age Research: NAD+ supplementation is now being recognized as a way to support almost every aspe

BOCA RATON, Fla.--(BUSINESS WIRE)--The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that its Deseyne® daily disposable contact lens technology for presbyopia with Extended Depth of Focus (EDOF) is this year’s recipient of the “Best New Technology Solution - Ophthalmology” in the 2026 MedTech Breakthrough Awards. The MedTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the

FDA Commissioner Marty Makary is expected to be fired from his role, according to multiple media reports. The plans haven’t been finalized and could still change, said the Wall Street Journal , which was first to report the news. Representatives for the White House and Makary didn’t immediately respond to requests for comment on Friday. Other outlets issued similar reports Friday, with Bloomberg News saying that Makary’s ouster could be followed by other changes at the FDA. Makary has experience

Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an “extraordinary loss” of 149.4 billion Japanese yen ($950 million) after overpromising demand for its ADCs to third-party manufacturers. The Japanese company postponed its earnings on April 24 after it said it needed to further assess some issues with its cancer drug supply chains. The postponement sent its stock tumbling by about 10% that day. On Friday, Daiichi said it’s cutting its operati

Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery ApplicationsTYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue Medical" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, co

Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoMira Diagnostics LLC ("CoMira"), has finalized a lease agr

SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results and provides an update on recent corporate developments for the first quarter ended March 31, 2026. "During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare dise

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the “Existing Warrants”) to purchase up to an aggregate of 8,719,928 shares of common s

FIREFLY-2 is the largest study ever conducted in front-line pLGG Trial aims to extend OJEMDA's indication beyond relapsed/refractory setting to address significant unmet need; topline data expected by mid-2027 BOSTON, May 8, 2026 /PRNewswire/ -- Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the FIREFLY-2 clinical trial, which is evaluating the efficacy, safety and tolerability of tovorafenib vs standard of care chemotherapy in th

Summit PD-1xVEGF's interim trial miss, UCB's $2 billion acquisition of Candid Therapeutics, and J&J's CAR-T pipeline cull made our news this week. Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. UCB will pay $2 billion upfront to buy Candid Therapeutics, which has aggregated a group of Chinese assets. Johnson & Johnson eliminated two CD20 CAR-T programs that it licensed from Sino-American biotech AbelZeta Pharma. And more.1.